基于体内外相结合的中药配伍减毒研究思路探讨
|
摘要
中药配伍减毒在人体内的作用机制主要有药物作用受体调节、药物代谢组学的影响、药物蛋白组学的影响、药物基因组学的影响。配伍药物在体内会改变有毒中药发挥药效物质的分布表现、药物浓度和人体对药物的吸收,同时可以改变有毒物质的分子结构,从而达到减毒增效的目的。体外机制包括组织器官结构和细胞分子水平的影响,Caco-2细胞模型、肝肠微粒体模型、肠道菌代谢模型可以很好地解释体外机制。总之,中药在配伍过程中药效及毒性均会发生一定变化,变化的具体方式需要体内及体外共同研究确定,进而充分了解药物的毒性改变,对中药配伍研究及中医药发展具有重要意义。
The mechanism of reducing toxicity of compatibility of Chinese materia medica in the human body mainly includes the regulation of Chinese materia medica receptors,the influence of Chinese materia medica metabolomics,the influence of Chinese materia medica proteomics,and the influence of pharmacogenomics. Compatibility of Chinese materia medica in the body will change the distribution of toxic Chinese materia medica,the concentration of Chinese materia medica and the absorption of Chinese materia medica by the human body,and at the same time can change the molecular structure of toxic substances,thereby achieving the purpose of reducing toxicity and increasing efficiency. In vitro mechanisms include tissue organ structure and cellular molecular level effects. Caco-2 cell models,liver-intestinal microsome models,and intestinal metabolic models can well explain in vitro mechanisms. In short,the efficacy and toxicity of Chinese materia medica will change in the process of compatibility. The specific method of change needs to be determined together in vivo and in vitro,so as to fully understand the toxicity change of Chinese materia medica,which is of great significance to the research of Chinese materia medica compatibility and the development of Chinese medicine.
The mechanism of reducing toxicity of compatibility of Chinese materia medica in the human body mainly includes the regulation of Chinese materia medica receptors,the influence of Chinese materia medica metabolomics,the influence of Chinese materia medica proteomics,and the influence of pharmacogenomics. Compatibility of Chinese materia medica in the body will change the distribution of toxic Chinese materia medica,the concentration of Chinese materia medica and the absorption of Chinese materia medica by the human body,and at the same time can change the molecular structure of toxic substances,thereby achieving the purpose of reducing toxicity and increasing efficiency. In vitro mechanisms include tissue organ structure and cellular molecular level effects. Caco-2 cell models,liver-intestinal microsome models,and intestinal metabolic models can well explain in vitro mechanisms. In short,the efficacy and toxicity of Chinese materia medica will change in the process of compatibility. The specific method of change needs to be determined together in vivo and in vitro,so as to fully understand the toxicity change of Chinese materia medica,which is of great significance to the research of Chinese materia medica compatibility and the development of Chinese medicine.
引文
[1]王君明,崔瑛.中药配伍减毒的研究现状及对策[J].时珍国医国药,2012,23(2):474-476.
[2]李彦文,李志勇,刘会永,等.中药配伍减毒研究的新思路[J].中国实验方剂学杂志,2012,17(20):321-324.
[3]马国海,赵琳,于军,等.中药配伍减毒的研究进展[J].江西中医药,2014,64(2):70-72.
[4]马哲,梁茂新.中药配伍减毒增效研究现状、问题与思考[J].辽宁中医药大学学报,2011,13(8):187-190.
[5]李军生,路燕,邹义英.中药配伍减毒及其应用[J].中医杂志,2010,60(S1):43-45.
[6]刘建群,王雪梅,刘一文,等.基于影响药物代谢的中药配伍研究进展[J].中国实验方剂学杂志,2014,20(19):221-224.
[7]刘蒙竹,张新龙,潘林海,等.清络通痹方中雷公藤配伍监督的化学基础研究[J].中国实验方剂学杂志,2014,20(7):107-112.
[8]魏光敏.人参养荣汤对气阴两虚型肺癌化疗的增效减毒[J].中国实验方剂学杂志,2013,19(5):312-316.
[9]FU Q,HUANG X,SHU B,et al. Inhibition of mitochondrial respiratory chain is involved in triptolide-induced liver injury[J]. Fitoterapia,2011,82(2):1241-1248.
[10]XUE X,GONG L K,QI X M. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity[J]. Toxicology Letters,2011,205(1):47-54.
[11]ZHOU W J,CHAI Z,WANG Y H. Protective effect of Guipi Tang on acute liver injury induced by ethanol extract from tripterygium wilfordii in rats[J]. Chinese Journal of Experimental Traditional Medical Formulae,2012,18(9):169-171.
[12]王利勤,杨沛华,万海同,等.基于中药配伍理论探析附子甘草配伍相关性研究及进展[J].世界科学技术——中医药现代化,2018,20(5):666-671.
[13]杨苗苗,杨霖,李孝栋.乌头安全有效性研究进展及其临床应用前景[J].药学研究,2018,37(3):125-133.
[14]吴青青,陈彦,蔡垠,等.羊藿三七提取物中主成分淫羊藿苷的肠吸收研究[J].中成药,2012,34(11):2103-2106.
[15]梁瑞峰,张峰,李更生,等.吴茱萸对黄连有效成分在大鼠体内组织分布的影响[J].中国实验方剂学杂志,2016,22(23):89-93.
[16]王喜军.基于药物代谢组学的中药及方剂中组分间协同增效作用[J].中国天然药物,2009,7(2):90.
[2]李彦文,李志勇,刘会永,等.中药配伍减毒研究的新思路[J].中国实验方剂学杂志,2012,17(20):321-324.
[3]马国海,赵琳,于军,等.中药配伍减毒的研究进展[J].江西中医药,2014,64(2):70-72.
[4]马哲,梁茂新.中药配伍减毒增效研究现状、问题与思考[J].辽宁中医药大学学报,2011,13(8):187-190.
[5]李军生,路燕,邹义英.中药配伍减毒及其应用[J].中医杂志,2010,60(S1):43-45.
[6]刘建群,王雪梅,刘一文,等.基于影响药物代谢的中药配伍研究进展[J].中国实验方剂学杂志,2014,20(19):221-224.
[7]刘蒙竹,张新龙,潘林海,等.清络通痹方中雷公藤配伍监督的化学基础研究[J].中国实验方剂学杂志,2014,20(7):107-112.
[8]魏光敏.人参养荣汤对气阴两虚型肺癌化疗的增效减毒[J].中国实验方剂学杂志,2013,19(5):312-316.
[9]FU Q,HUANG X,SHU B,et al. Inhibition of mitochondrial respiratory chain is involved in triptolide-induced liver injury[J]. Fitoterapia,2011,82(2):1241-1248.
[10]XUE X,GONG L K,QI X M. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity[J]. Toxicology Letters,2011,205(1):47-54.
[11]ZHOU W J,CHAI Z,WANG Y H. Protective effect of Guipi Tang on acute liver injury induced by ethanol extract from tripterygium wilfordii in rats[J]. Chinese Journal of Experimental Traditional Medical Formulae,2012,18(9):169-171.
[12]王利勤,杨沛华,万海同,等.基于中药配伍理论探析附子甘草配伍相关性研究及进展[J].世界科学技术——中医药现代化,2018,20(5):666-671.
[13]杨苗苗,杨霖,李孝栋.乌头安全有效性研究进展及其临床应用前景[J].药学研究,2018,37(3):125-133.
[14]吴青青,陈彦,蔡垠,等.羊藿三七提取物中主成分淫羊藿苷的肠吸收研究[J].中成药,2012,34(11):2103-2106.
[15]梁瑞峰,张峰,李更生,等.吴茱萸对黄连有效成分在大鼠体内组织分布的影响[J].中国实验方剂学杂志,2016,22(23):89-93.
[16]王喜军.基于药物代谢组学的中药及方剂中组分间协同增效作用[J].中国天然药物,2009,7(2):90.